cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2021-3084cardiovascular-3084Research ArticleБИОБАНКИРОВАНИЕBIOBANKINGБиобанк как ключевой компонент сопровождения научных исследований во фтизиатрии и инфектологииBiobank as a key component of supporting research in phthisiology and infectious diseaseshttps://orcid.org/0000-0001-8014-1230УмпелеваТ. В.UmpelevaT. V.

Кандидат биологических наук, ведущий научный сотрудник отдела микробиологии и доклинических исследований.

Екатеринбург

The researcher , department of Microbiology and Preclinical research.

Yekaterinburg

tumpeleva@ya.ruhttps://orcid.org/0000-0001-6085-6466ВахрушеваД. В.VakhrushevaD. V.

Кандидат биологических наук, заведующий отделом микробиологии и доклинических исследований.

Екатеринбург

The head , department of Microbiology and Preclinical research.

Yekaterinburg

vakhrusheva@urniif.ruhttps://orcid.org/0000-0003-0366-9634СкорняковС. Н.SkornyakovS. N.

Доктор медицинских наук, заведующий научно-клиническим отделом.

Екатеринбург

The head , Scientific and clinical department.

Yekaterinburg

sns@urniif.ruФГБУ Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний Минздрава РоссииNational Medical Research Center of Phthisiopulmonology and Infectious Diseases20210801202220830843084Copyright © Умпелева Т.В., Вахрушева Д.В., Скорняков С.Н., 20222022Умпелева Т.В., Вахрушева Д.В., Скорняков С.Н.Umpeleva T.V., Vakhrusheva D.V., Skornyakov S.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/3084

Проведение фундаментальных и клинических исследований в области туберкулеза является важным этапом на пути к снижению показателей заболеваемости и смертности от этой инфекции, однако доступ к достаточному количеству качественных паспортизованных образцов, необходимых для проведения исследований, является нерешенной проблемой отечественной фтизиатрии. Настоящий обзор посвящен теме биобанкирования, как ключевого компонента современных исследований в области персонализированной медицины, а также вопросам состояния и перспектив развития этого направления во фтизиатрии и сочетанной с туберкулезом инфекционной патологии.

Conducting fundamental and clinical research in the field of tuberculosis is an important step towards reducing related morbidity and mortality, but access to a sufficient number of high-quality samples required for research is an unsolved problem in Russia. This review is devoted to biobanking as a key component of modern research in personalized medicine, as well as to the status and prospects for developing this area in phthisiology and infectious diseases combined with tuberculosis.

туберкулезбиобанксочетанная патологияперсонализированная медицинаtuberculosisbiobankcombined pathologypersonalized medicineРабота выполнена в рамках государственного задания, рег. № НИОКТР АААА-А18-П8072390015-9The work was carried out within the state assignment № AAAA-A18-118072390015-9ReferencesLoft S, Poulsen HE. Cancer risk and oxidative DNA damage in man. J Mol Med (Berl). 1996;74(6):297-312. doi: 10.1007/BF00207507.Loft S, Poulsen HE. Cancer risk and oxidative DNA damage in man. J Mol Med (Berl). 1996;74(6):297-312. doi: 10.1007/BF00207507.Coppola L, Cianflone A, Grimaldi AM, et al. Biobanking in health care: evolution and future directions. J Transl Med. 2019;17(1):172. doi:10.1186/s12967-019-1922-3.Coppola L, Cianflone A, Grimaldi AM, et al. Biobanking in health care: evolution and future directions. J Transl Med. 2019;17(1):172. doi:10.1186/s12967-019-1922-3.Garcia M, Downs J, Russell A, et al. Impact of biobanks on research outcomes in rare diseases: a systematic review. Orphanet J Rare Dis. 2018;13(1):202. doi:10.1186/s13023-018-0942-z.Garcia M, Downs J, Russell A, et al. Impact of biobanks on research outcomes in rare diseases: a systematic review. Orphanet J Rare Dis. 2018;13(1):202. doi:10.1186/s13023-018-0942-z.Kinkorova J. Biobanks in the era of personalized medicine: objectives, challenges, and innovation: Overview. EPMA J. 2016;7(1):4. doi:10.1186/s13167-016-0053-7Kinkorova J. Biobanks in the era of personalized medicine: objectives, challenges, and innovation: Overview. EPMA J. 2016;7(1):4. doi:10.1186/s13167-016-0053-7Patil S, Majumdar B, Awan KH, et al. Cancer oriented biobanks: A comprehensive review. Oncol Rev. 2018;12(1):357 doi:10.4081/oncol.2018.357.Patil S, Majumdar B, Awan KH, et al. Cancer oriented biobanks: A comprehensive review. Oncol Rev. 2018;12(1):357 doi:10.4081/oncol.2018.357.Sidorenkov G, Nagel J, Meijer C, et al. The OncoLifeS data-biobank for oncology: a comprehensive repository of clinical data, biological samples, and the patient’s perspective. J Transl Med. 2019;17(1):374. doi:10.1186/s12967-019-2122-x.Sidorenkov G, Nagel J, Meijer C, et al. The OncoLifeS data-biobank for oncology: a comprehensive repository of clinical data, biological samples, and the patient’s perspective. J Transl Med. 2019;17(1):374. doi:10.1186/s12967-019-2122-x.Hanif Z, Sufiyan N, Patel M, et al. Role of biobanks in transplantation. Ann Med Surg (Lond). 2018;28:30-3. doi:10.1016/j.amsu.2018.02.0077 Hanif Z, Sufiyan N, Patel M, et al. Role of biobanks in transplantation. Ann Med Surg (Lond). 2018;28:30-3. doi:10.1016/j.amsu.2018.02.007Mercuri A, Turchi S, Borghini A, et al. Nitrogen biobank for cardiovascular research. Curr Cardiol Rev. 2013;9(3):253-9. doi: 10.2174/1573403x113099990035.Mercuri A, Turchi S, Borghini A, et al. Nitrogen biobank for cardiovascular research. Curr Cardiol Rev. 2013;9(3):253-9. doi: 10.2174/1573403x113099990035.Betsou F, Parida SK, Guillerm M. Infectious diseases biobanking as a catalyst towards personalized medicine: Mycobacterium tuberculosis paradigm. Tuberculosis (Edinb). 2011;91(6):524-32. doi:10.1016/j.tube.2011.07.006.Betsou F, Parida SK, Guillerm M. Infectious diseases biobanking as a catalyst towards personalized medicine: Mycobacterium tuberculosis paradigm. Tuberculosis (Edinb). 2011;91(6):524-32. doi:10.1016/j.tube.2011.07.006.Brankovic I, Malogajski J, Morre SA. Biobanking and translation of human genetics and genomics for infectious diseases. Appl Transl Genom. 2014;3(2):30-5. doi: 10.1016/j.atg.2014.04.001.Brankovic I, Malogajski J, Morre SA. Biobanking and translation of human genetics and genomics for infectious diseases. Appl Transl Genom. 2014;3(2):30-5. doi: 10.1016/j.atg.2014.04.001.Muller H, Dagher G, Loibner M, et al. Biobanks for life sciences and personalized medicine: importance of standardization, biosafety, biosecurity, and data management. Curr Opin Biotechnol. 2020;65:45-51. doi: 10.1016/j.copbio.2019.12.004.Muller H, Dagher G, Loibner M, et al. Biobanks for life sciences and personalized medicine: importance of standardization, biosafety, biosecurity, and data management. Curr Opin Biotechnol. 2020;65:45-51. doi: 10.1016/j.copbio.2019.12.004.Wood MR, Yu EA, Mehta S. The human microbiome in the fight against tuberculosis. Am J Trop Med Hyg. 2017;96(6):1274-84. doi:10.4269/ajtmh.16-0581.Wood MR, Yu EA, Mehta S. The human microbiome in the fight against tuberculosis. Am J Trop Med Hyg. 2017;96(6):1274-84. doi:10.4269/ajtmh.16-0581.ISBER Best Practices: Recommendations for repositories. LD Campbell (ed). 4th edition. ISBER. 2018:103.ISBER Best Practices: Recommendations for repositories. LD Campbell (ed). 4th edition. ISBER. 2018:103.Beuth Verlag. ISO 20387:2018-08 Biotechnology — Biobanking — General requirements for biobanking. 2018.Beuth Verlag. ISO 20387:2018-08 Biotechnology — Biobanking — General requirements for biobanking. 2018.Capocasa M, Anagnostou P, D’Abramo F, et al. Samples and data accessibility in research biobanks: an explorative survey. Peer J. 2016;4:e1613. doi:10.7717/peerj.1613.Capocasa M, Anagnostou P, D’Abramo F, et al. Samples and data accessibility in research biobanks: an explorative survey. Peer J. 2016;4:e1613. doi:10.7717/peerj.1613.Doucet M, Becker KF, Bjorkman J, et al. Quality Matters: 2016 Annual conference of the national infrastructures for biobanking. Biopreserv Biobank. 2017;15(3):270-6. doi:10.1089/bio.2016.0053.Doucet M, Becker KF, Bjorkman J, et al. Quality Matters: 2016 Annual conference of the national infrastructures for biobanking. Biopreserv Biobank. 2017;15(3):270-6. doi:10.1089/bio.2016.0053.Ransohoff DF, Gourlay ML. Sources of bias in specimens for research about molecular markers for cancer. J Clin Oncol. 2010;28(4):698-704. doi:10.1200/JC0.2009.25.6065.17 Ransohoff DF, Gourlay ML. Sources of bias in specimens for research about molecular markers for cancer. J Clin Oncol. 2010;28(4):698-704. doi:10.1200/JC0.2009.25.6065.Ciaburri M, Napolitano M, Bravo E. Business planning in biobanking: How to implement a tool for sustainability. Biopreserv Biobank. 2017; 15(1):46-56. doi:10.1089/bio.2016.0045.Ciaburri M, Napolitano M, Bravo E. Business planning in biobanking: How to implement a tool for sustainability. Biopreserv Biobank. 2017; 15(1):46-56. doi:10.1089/bio.2016.0045.Драпкина О. М. Российская “Национальная ассоциация биобанков и специалистов по биобанкированию” — инструмент интеграции российских биобанков и повышения эффективности биомедицинских исследований. Кардиоваскулярная терапия и профилактика. 2020;19(6):2757 doi:10.15829/1728-8800-2020-2757Drapkina OM. Russian National Association of Biobanks and Biobanking Specialists — a tool for integrating Russian biobanks and increasing the efficiency of biomedical research. Cardiovascular Therapy and Prevention. 2020;19(6):2757 (In Russ.) doi:10.15829/1728-8800-2020-2757Anisimov SV, Meshkov AN, Glotov AS, et al. National Association of Biobanks and Biobanking Specialists: New Community for Promoting Biobanking Ideas and Projects in Russia. Biopreservation and Biobanking. 2021;73-82. doi: 10.1089/bio.2020.0049.Anisimov SV, Meshkov AN, Glotov AS, et al. National Association of Biobanks and Biobanking Specialists: New Community for Promoting Biobanking Ideas and Projects in Russia. Biopreservation and Biobanking. 2021;73-82. doi: 10.1089/bio.2020.0049.Swanepoel C, Snyders C, Isaacs S, et al. Biomarker discovery for diagnosis and treatment of tuberculosis: a role for biobanking? J Biorepos Sci Appl Med. 2015;3(1):47-56. doi: 10.2147/BSAM.S64571.Swanepoel C, Snyders C, Isaacs S, et al. Biomarker discovery for diagnosis and treatment of tuberculosis: a role for biobanking? J Biorepos Sci Appl Med. 2015;3(1):47-56. doi: 10.2147/BSAM.S64571.Markedly Accelerating Research with Knowledge of Tuberculosis Biomarkers https://www.mark-tb.org/. (05 Okt 2021).Markedly Accelerating Research with Knowledge of Tuberculosis Biomarkers https://www.mark-tb.org/. (05 Okt 2021).Нечаева О. Б. Эпидемическая ситуация по туберкулезу в России. Туберкулёз и болезни лёгких. 2018;96(8):15-24. doi:10.21292/2075-1230-2018-96-8-15-24.Nechaeva OB. TB situation in Russia. Tuberculosis and Lung Diseases. 2018;96(8): 15-24. (In Russ.) doi:10.21292/2075-1230-2018-96-8-15-24.Бурмистрова И. А., Самойлова А. Г., Тюлькова Т. Е. и др. Лекарственная устойчивость M. tuberculosis (исторические аспекты, современный уровень знаний). Туберкулёз и болезни лёгких. 2020;98(1):54-61. doi:10.21292/2075-1230-2020-98-1-54-61.Burmistrova IA, Samoylova AG, Tyulkova TE, et al. Drug resistance of M. tuberculosis (historical aspects, current level of knowledge). Tuberculosis and Lung Diseases. 2020;98(1):54-61. (In Russ.) doi:10.21292/2075-1230-2020-98-1-54-61.Mahomed S, Padayatchi N, Singh J, et al. Precision medicine in resistant Tuberculosis: Treat the correct patient, at the correct time, with the correct drug. J Infect. 2019;78(4):261-8. doi:10.1016/j.jinf.2019.03.006.Mahomed S, Padayatchi N, Singh J, et al. Precision medicine in resistant Tuberculosis: Treat the correct patient, at the correct time, with the correct drug. J Infect. 2019;78(4):261-8. doi:10.1016/j.jinf.2019.03.006.Нечаева О. Б. Социально значимые инфекционные заболевания, представляющие биологическую угрозу населению России. Туберкулёз и болезни лёгких. 2019;97( 11):7-17 doi:10.21292/2075-1230-2019-97-11-7-17Nechaeva OB. Socially important infectious diseases posing a biological threat to the population of Russia. Tuberculosis and Lung Diseases. 2019;97(11):7-17 (In Russ.) doi:10.21292/2075-1230-2019-97-11-7-17Гельберг И. С., Алексо Е. Н., Вольф С. Б. и др. Характеристика туберкулезного процесса с множественной лекарственной устойчивостью и эффективность его лечения у пациентов при наличии отягощающих факторов. Туберкулез и болезни легких. 2019;97(6):51-2. doi: 10.21292/2075-1230-2019-97-6-51-52.27 Gelberg IS, Alekso EN, Volf SB, et al. Description of the course of multiple drug resistant tuberculosis and efficacy of its treatment in the patients with confounding factors. Tuberculosis and Lung Diseases. 2019;97(6):51-2. (In Russ.) doi: 10.21292/2075-1230-2019-97-6-51-52.Казимирова Н. Е., Артемьев А. М., Амирова З. Р. и др. Проблемы диагностики туберкулеза у пациентов с разной ко-морбидностью. Туберкулез и болезни легких. 2019;97(6):61-2. doi:10.21292/2075-1230-2019-97-6-61-62.Kazimirova NE, Artemiev AM, Amirova ZR, et al. Problems of diagnostics of tuberculosis in the patients with various comorbidities. Tuberculosis and Lung Diseases. 2019;97(6):61-2. (In Russ.) doi:10.21292/2075-1230-2019-97-6-61-62.Бородулина Е. А., Вдоушкина Е. С., Кузнецова А. Н. и др. Особенности коморбидной патологии (ВИЧ/туберкулез) при летальных исходах. ВИЧ-инфекция и иммуносупрессии. 2019; 11 (4):70-8. doi: 10.22328/2077-9828-2019-11-4-70-78.Borodulina EA, Vdoushkina ES, Kuznetsova AN, et al. Features of concominant HIV/tuberculosis diseases with fatal outcomes. HIV Infection and Immunosuppressive Disorders. 2019; 11 (4):70-8. (In Russ.) doi: 10.22328/2077-9828-2019-11-4-70-78.Колпакова Т. А. Проблема коморбидности в клинике легочного туберкулеза. Бюллетень ВСНЦ СО РАМН. 2011;2(78):48-51.Kolpakova T. The problem of comorbidity in the clinic of pulmonary tuberculosis. Acta Biomedica Scientifica (East Siberian Biomedical Journal) 2011;2(78):48-51. (In Russ.)Rose R, Nolan DJ, Maidji E, et al. Eradication of HIV from tissue reservoirs: challenges for the cure. AIDS Res Hum Retroviruses. 2018;34(1):3-8. doi:10.1089/AID.2017.0072.Rose R, Nolan DJ, Maidji E, et al. Eradication of HIV from tissue reservoirs: challenges for the cure. AIDS Res Hum Retroviruses. 2018;34(1):3-8. doi:10.1089/AID.2017.0072.Denton PW, Sogaard OS, Tolstrup M. Impacts of HIV cure interventions on viral reservoirs in tissues. Front Microbiol. 2019;10:1956. doi:10.3389/fmicb.2019.01956.Denton PW, Sogaard OS, Tolstrup M. Impacts of HIV cure interventions on viral reservoirs in tissues. Front Microbiol. 2019;10:1956. doi:10.3389/fmicb.2019.01956.Murray M, Nardell E. Molecular epidemiology of tuberculosis: achievements and challenges to current knowledge. Bull World Health Organ. 2002;80(6):477-82.Murray M, Nardell E. Molecular epidemiology of tuberculosis: achievements and challenges to current knowledge. Bull World Health Organ. 2002;80(6):477-82.Pourostadi M, Rashedi J, Poor BM, et al. Tuberculosis control and role of molecular epidemiology studies in Iran: A Systematic Review. Tanaffos. 2017;16(3):190-200.Pourostadi M, Rashedi J, Poor BM, et al. Tuberculosis control and role of molecular epidemiology studies in Iran: A Systematic Review. Tanaffos. 2017;16(3):190-200.Talarico S, Silk B, Shaw B, Cilnis M. Whole-genome sequencing for investigation of recent TB transmission in the United States. A training module https://www.cdc.gov/tb/programs/genotyping/default.htm. (05 Okt 2021).Talarico S, Silk B, Shaw B, Cilnis M. Whole-genome sequencing for investigation of recent TB transmission in the United States. A training module https://www.cdc.gov/tb/programs/genotyping/default.htm. (05 Okt 2021).Vluggen C, Soetaert K, Groenen G, et al. Molecular epidemiology of Mycobacterium tuberculosis complex in Brussels, 20102013. PLoS One. 2017;12(2):e0172554. doi: 10.1371/journal.pone.0172554.Vluggen C, Soetaert K, Groenen G, et al. Molecular epidemiology of Mycobacterium tuberculosis complex in Brussels, 20102013. PLoS One. 2017;12(2):e0172554. doi: 10.1371/journal.pone.0172554.Mokrousov I, Vyazovaya A, Solovieva N, et al. Trends in molecular epidemiology of drug-resistant tuberculosis in Republic of Karelia, Russian Federation. BMC. Microbiol. 2015;15:279. doi:10.1186/s12866-015-0613-3.Mokrousov I, Vyazovaya A, Solovieva N, et al. Trends in molecular epidemiology of drug-resistant tuberculosis in Republic of Karelia, Russian Federation. BMC. Microbiol. 2015;15:279. doi:10.1186/s12866-015-0613-3.Pasechnik O, Dymova MA, Stasenko VL, et al. Molecular & genetic characteristics of Mycobacterium tuberculosis strains circulating in the southern part of West Siberia. Indian J Med Res. 2017;146:49-55. doi:10.4103/ijmr.IJMR_162_16.Pasechnik O, Dymova MA, Stasenko VL, et al. Molecular & genetic characteristics of Mycobacterium tuberculosis strains circulating in the southern part of West Siberia. Indian J Med Res. 2017;146:49-55. doi:10.4103/ijmr.IJMR_162_16.Sinkov V, Ogarkov O, Mokrousov I, et al. New epidemic cluster of pre-extensively drug resistant isolates of Mycobacterium tuberculosis Ural family emerging in Eastern Europe. BMC Genomics. 2018;19:762. doi:10.1186/s12864-018-5162-3.Sinkov V, Ogarkov O, Mokrousov I, et al. New epidemic cluster of pre-extensively drug resistant isolates of Mycobacterium tuberculosis Ural family emerging in Eastern Europe. BMC Genomics. 2018;19:762. doi:10.1186/s12864-018-5162-3.Umpeleva T, Belousova K, Golubeva L, et al. Molecular characteristics of Mycobacterium tuberculosis in the “closed” Russian town with limited population migration. Infect Genet Evol. 2020;79:104174. doi:10.1016/j.meegid.2020.104174.Umpeleva T, Belousova K, Golubeva L, et al. Molecular characteristics of Mycobacterium tuberculosis in the “closed” Russian town with limited population migration. Infect Genet Evol. 2020;79:104174. doi:10.1016/j.meegid.2020.104174.Семененко Т. А., Ананьина Ю. В., Боев Б. В., Гинцбург А. Л. Банки биологических ресурсов в системе фундаментальных эпидемиологических и клинических исследований. Журнал “Вестник РАМН”. 2011;10:5-9.Semenenko TA, Anan’ina YuV, Boev BV, Gintsburg AL. Banks of biological resources in the system of basic epidemiological and clinical studies. Annals of the Russian Academy of Medical Sciences. 2011;10:5-9. (In Russ.)

The authors declare that there are no conflicts of interest present.